Valneva: 26% increase in product sales in 2023

(CercleFinance.com) - Valneva is reporting total sales of E153.
7m for 2023, well below theE361.3m in 2022, a year which nevertheless included E280m in revenues linked to Covid-19 vaccine supply agreements. NB: cp: -2.4%.

Product sales rose by 26% to E144.6m over the past year, and excluding Covid-19 vaccine sales, they increased by 63% to E138.9m.

For 2024, product sales are expected between E150m and E180m, subject to the availability of Ixiaro and third-party products, as well as the performance of Ixchiq sales during the vaccine's launch year in the US.


Copyright (c) 2024 CercleFinance.com. All rights reserved.